Skip to main content

Table 1 Characteristics of the study population

From: A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women

 

Controls (n = 4687)

Cases (n = 3663)

 

Frequency

Mean (SD) or %

Frequency

Mean (SD) or %

Age at enrollment (years)

4687

55.62 (12.01)

3663

54.94 (11.74)

Age at enrollment (years)

 18–29

24

0.51

30

0.82

 30–39

396

8.45

306

8.35

 40–49

1107

23.62

945

25.8

 50–59

1461

31.17

1087

29.68

 60–69

986

21.04

819

22.36

 70–79

609

12.99

433

11.82

 80+

104

2.22

43

1.17

DNA source

 Blood

1817

38.77

1961

53.54

 Mouthwash

2243

47.86

853

23.29

 Saliva

627

13.38

849

23.18

Study

 BWHS

2249

48.98

901

24.6

 WCHS

834

17.79

821

22.41

 CBCS

615

13.12

1408

38.44

 MEC

989

21.1

533

14.55

Location

 New Jersey (NJ)

573

12.23

613

16.73

 Northeast (except NJ)

1245

26.56

441

12.04

 South

1476

31.49

1720

46.96

 Midwest

238

5.08

200

5.46

 West

1155

24.64

689

18.81

Stage

 In situ

NA

 

376

10.26

 Invasive

NA

 

2528

69.01

 Unknown

NA

 

759

20.72

Tumor receptor status

 ER

  Positive

NA

 

1983

54.14

  Negative

NA

 

1098

29.98

  Unknown

NA

 

582

15.89

 PR

  Positive

NA

 

1580

43.13

  Negative

NA

 

1343

36.66

  Unknown

NA

 

740

20.2

 HER2

  Positive

NA

 

344

9.39

  Negative

NA

 

1356

37.02

  Unknown

NA

 

1963

53.59

 Triple negative

  Yes

NA

 

405

11.06

  No

NA

 

1613

44.03

  Unknown

NA

 

1645

44.91

  1. BWHS, Black Women’s Health Study; CBCS, Carolina Breast Cancer Study; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MEC, Multiethnic Cohort; NA, not applicable; PR, progesterone receptor; SD, standard deviation; WCHS, Women’s Circle of Health Study